Zieve's syndrome: Difference between revisions
Gerald Chi (talk | contribs) No edit summary |
Ochuko Ajari (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{SI}} | {{SI}} | ||
{{CMG}} | {{CMG}} | ||
| Line 10: | Line 8: | ||
==Historical Perspective== | ==Historical Perspective== | ||
Zieve's syndrome was initially described by Leslie Zieve in patients with a combination of [[alcoholic liver disease]], [[hemolytic anemia]] and [[hypertriglyceridemia]].<ref name="pmid13521581">{{cite journal | author = ZIEVE L | title = Jaundice, hyperlipemia and hemolytic anemia: a heretofore unrecognized syndrome associated with alcoholic fatty liver and cirrhosis | journal = [[Annals of Internal Medicine]] | volume = 48 | issue = 3 | pages = 471–96 | year = 1958 | month = March | pmid = 13521581 | doi = | url = http://www.annals.org/article.aspx?volume=48&page=471 | issn = }}</ref> | Zieve's syndrome was initially described by Leslie Zieve in patients with a combination of [[alcoholic liver disease]], [[hemolytic anemia]] and [[hypertriglyceridemia]].<ref name="pmid13521581">{{cite journal | author = ZIEVE L | title = Jaundice, hyperlipemia and hemolytic anemia: a heretofore unrecognized syndrome associated with alcoholic fatty liver and cirrhosis | journal = [[Annals of Internal Medicine]] | volume = 48 | issue = 3 | pages = 471–96 | year = 1958 | month = March | pmid = 13521581 | doi = | url = http://www.annals.org/article.aspx?volume=48&page=471 | issn = }}</ref> | ||
==Pathophysiology== | |||
The proposed mechanism of the characteristic haemolytic anaemia in Zieve's syndrome is due to alteration of the red cell metabolism, namely pyruvate kinase instability leaving them susceptible to circulating [[hemolysin]] such as [[Lysophosphatidylcholine|lysolecithin]].<ref>{{Cite journal|last=Melrose|first=W. D.|last2=Bell|first2=P. A.|last3=Jupe|first3=D. M.|last4=Baikie|first4=M. J.|date=1990-01-01|title=Alcohol-associated haemolysis in Zieve's syndrome: a clinical and laboratory study of five cases|url=http://www.ncbi.nlm.nih.gov/pubmed/2208946|journal=Clinical and Laboratory Haematology|volume=12|issue=2|pages=159–167|issn=0141-9854|pmid=2208946}}</ref> Changes in membrane lipid compositions such as increased [[cholesterol]] and [[polyunsaturated fatty acid]] (PUFA) have been report during the hemolytic phase.<ref>{{Cite journal|last=Kunz|first=F.|last2=Stummvoll|first2=W.|date=1970-10-01|title=The significance of plasma phospholipids in Zieve syndrome|url=http://www.ncbi.nlm.nih.gov/pubmed/5531666|journal=Blut|volume=21|issue=4|pages=210–226|issn=0006-5242|pmid=5531666}}</ref> | |||
==Treatment== | |||
Definitive treatment for Zieve's syndrome is alcohol cessation. | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
[[Category:Hepatology]] | [[Category:Hepatology]] | ||
{{ | {{WH}} | ||
{{ | {{WS}} | ||
Revision as of 18:54, 6 June 2016
|
WikiDoc Resources for Zieve's syndrome |
|
Articles |
|---|
|
Most recent articles on Zieve's syndrome Most cited articles on Zieve's syndrome |
|
Media |
|
Powerpoint slides on Zieve's syndrome |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Zieve's syndrome at Clinical Trials.gov Trial results on Zieve's syndrome Clinical Trials on Zieve's syndrome at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Zieve's syndrome NICE Guidance on Zieve's syndrome
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Zieve's syndrome Discussion groups on Zieve's syndrome Patient Handouts on Zieve's syndrome Directions to Hospitals Treating Zieve's syndrome Risk calculators and risk factors for Zieve's syndrome
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Zieve's syndrome |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Zieve's syndrome is an acute metabolic condition that can occur during withdrawal from prolonged alcohol abuse. It is characterized by hemolytic anemia, hyperlipidemia, jaundice, and abdominal pain. The underlying cause is liver delipidation. This is distinct from alcoholic hepatitis which, however, may present simultaneously or develop later.
Historical Perspective
Zieve's syndrome was initially described by Leslie Zieve in patients with a combination of alcoholic liver disease, hemolytic anemia and hypertriglyceridemia.[1]
Pathophysiology
The proposed mechanism of the characteristic haemolytic anaemia in Zieve's syndrome is due to alteration of the red cell metabolism, namely pyruvate kinase instability leaving them susceptible to circulating hemolysin such as lysolecithin.[2] Changes in membrane lipid compositions such as increased cholesterol and polyunsaturated fatty acid (PUFA) have been report during the hemolytic phase.[3]
Treatment
Definitive treatment for Zieve's syndrome is alcohol cessation.
References
- ↑ ZIEVE L (1958). "Jaundice, hyperlipemia and hemolytic anemia: a heretofore unrecognized syndrome associated with alcoholic fatty liver and cirrhosis". Annals of Internal Medicine. 48 (3): 471–96. PMID 13521581. Unknown parameter
|month=ignored (help) - ↑ Melrose, W. D.; Bell, P. A.; Jupe, D. M.; Baikie, M. J. (1990-01-01). "Alcohol-associated haemolysis in Zieve's syndrome: a clinical and laboratory study of five cases". Clinical and Laboratory Haematology. 12 (2): 159–167. ISSN 0141-9854. PMID 2208946.
- ↑ Kunz, F.; Stummvoll, W. (1970-10-01). "The significance of plasma phospholipids in Zieve syndrome". Blut. 21 (4): 210–226. ISSN 0006-5242. PMID 5531666.